Purpose of review: Endolymphatic hydrops remains a significant cause of morbidity secondary to vertigo, hearing loss, and tinnitus. The purpose of this report is to summarize the most clinically relevant publications on endolymphatic hydrops over the past 2 years.
Recent findings: Hydrops has historically been a diagnosis of exclusion, but recent efforts has shown a role for MRI with intratympanic gadolinium. Cochrane reviews of intratympanic dexamethasone and gentamicin found inadequate level 1 evidence to support their use.
Summary: High-level evidence to guide therapy is lacking. MRI holds potential for definitive diagnosis.